Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 24Leukemia, Myeloid, Acute 16Myeloproliferative Disorders 15Polycythemia Vera 12Leukemia 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Myelodysplastic Syndromes 9Thrombocythemia, Essential 8Graft vs Host Disease 8Recurrence 6Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, T-Cell 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Bronchiolitis Obliterans Syndrome 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2

Interventions

ibrutinib 5ruxolitinib 3Sirolimus 3Mycophenolic Acid 3fludarabine 2asciminib 2Filgrastim 2Cyclophosphamide 2posaconazole 1pegfilgrastim 1montelukast 1axatilimab 1Whole-Body Irradiation 1Voriconazole 1Tomography, X-Ray Computed 1Specimen Handling 1Saline Solution 1Rituximab 1Respiratory Function Tests 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Panobinostat 1Methotrexate 1Mesna 1Infliximab 1Imatinib Mesylate 1Everolimus 1Erythropoietin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × ruxolitinib × 1 year × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03774082 2025-12-11

REACH 5

Novartis

Phase 2 Completed
46 enrolled 21 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡